Page results
-
Following on from the care failures highlighted in the 2021 report, ‘No One’s Listening’, the Sickle Cell Society have taken a deeper look at sickle cell nursing care
-
A research study has found that patients who get their chest X-ray results immediately are diagnosed in half the usual time.
-
UCLH Director of Research Professor Bryan Williams has been elected as the next President of the International Society of Hypertension (ISH).
-
Men currently attending a hospital outpatient clinic for prostate hormone injections every 3 or 6 months will be advised that (unless not clinically appropriate) their next injection will be administered at a local GP practice, usually by the practice nurse.
-
All semen analysis referrals should be made via the NHS e-Referral Service (e-RS). We will no longer be able to book semen analysis appointments through direct requests from patients or GP surgeries via email.
-
We are now administering new COVID-19 treatments for patients at highest risk in the community. The service can prescribe oral antivirals to be taken at home, and give intravenous antibody treatments at the hospital.
-
Minimally invasive therapies for prostate cancer which remove the cancer while leaving the rest of the prostate intact are beneficial for patients and cost effective according to new research.
-
How we use your information at UCLH: what you need to know
-
The Hyperacute Stroke Unit (HASU) and the Transient Ischaemic Attack (TIA) services were relocated from the seventh floor of University College Hospital to The National Hospital for Neurology and Neurosurgery (NHNN) on 20 March 2020 as part of UCLH’s response to the Covid-19 pandemic.
-
The first ever treatment for the rare neurodegenerative disease Friedreich’s ataxia – for which UCLH and UCL led the UK trial – has been approved for use in the UK by the medicines’ regulator.
File results
-
FOI/2023/0220 - Internally produced patient information leaflets
-
FOI/2023/0210 - Top five drugs that expired by value
-
FOI/2023/0214 - Patients waiting over 78 weeks for elective care
-
FOI/2023/0215 - British sign language procurement and communications
-
FOI/2023/0217 - Integration platform(s) at the Trust
-
FOI/2023/0218 - System for discharge letters, diagnostic reporting, digital dictation & bed management
-
FOI/2023/0225 - Usage of Dabrafenib + Trametinib in cancer treatment
-
FOI/2023/0227 - Number of radiographers and nuclear medicine clinical scientists at Trust
-
FOI/2023/0226 - Treatment with Nivolumab
-
FOI/2023/0124 - Clinical decision support in e-prescribing, Observations vital signs, Oncology e-prescribing and Diagnostic imaging systems